Michael Christel

In this video episode, Pratap Khedkar, PhD, CEO of ZS, joins the Pharm Exec Podcast to discuss three distinct industry trends and strategy shifts converging at the moment amid the backdrop of US-driven global policy change.

Pharm Exec’s 21st Annual Pipeline Report examines emerging drug development classes, treatment modalities, and expansion pursuits in five therapeutic settings ripe for next-gen innovation.

Ken Banta and Andrew Hall share insights on leading through uncertainty—covering culture, capital, risk, and the regulatory headwinds influencing key decisions in drug development.

Jim Greffet, head of sustainability at Eli Lilly, on establishing ESG as a core business driver—and key complement to manufacturer long-term growth pursuits.

Inside Brent Saunders’ return run as CEO of Bausch + Lomb—and setting the storied eye care pharma on a bold path of reinvention.

With patent cliffs fast approaching, asset differentiation will be king.

Q&A with Krishna Kanumuri, CEO of Sai Life Sciences, on steering a contract development and management organization through growth, scale-up, and the shifting global supply chain in pharma.

Q&A with Harry Totonis, CEO and chairman of ConnectiveRx, on embracing change and seeking better solutions amid today’s challenging playing field for patient access.

Avak Kahvejian, PhD, a general partner with biotech incubator Flagship Pioneering, discusses how AI is rearchitecting methods—and mindsets—in drug discovery and development.

With healthcare at a key crossroads of policy, technology, and science, Sanofi CEO Paul Hudson shares the Big Pharma’s formula for navigating the new age of innovation, where running from risk is not an option.

Ways biopharma organizations and media brands can leverage coverage opportunities to help achieve respective audience goals and missions.

Ken Banta, founder and CEO of The Vanguard Network, reveals the mindsets and moves biopharma leaders need to not just endure—but rise above—the current age of industry disruption.

How a layered approach—tapping new avenues from earned media—can go a long way in boosting the brand engagement interplay between pharma companies and physicians.

A timeline of key developments surrounding Sarepta Therapeutics' Duchenne muscular dystrophy drug Elevidys, and the potential future impacts for gene therapy regulation and market access.

Q&A with Model N's Michael Grosberg drills deeper into the new US drug pricing directives, including challenges in implementation, the potential unintended consequences, and how these actions could spark the shift to outcomes-based contracting in healthcare.

With a backdrop of mounting industry disruption and transition, Pharm Exec’s latest listing of the top global biopharma sales producers, its 25th, points to the importance of organizations doubling down on what they do best while seizing new opportunities to innovate.

Dive into a sampling of data drivers—and expanded insights—poised to impact and reshape our annual leaderboard.

Insights on ways pharmacy benefit managers can tap earned media to enhance their reputation—and demonstrate value through transparency, storytelling, and leveraging data to improve patient care.

Our exclusive poll captures today's top trends and perspectives—shaped by those pharma decision-makers impacted the most.

The latest Q&A installment in Pharm Exec's earned media series details key strategies for leveraging breaking news at industry trade shows, including the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting.

Milan Kalawadia, CEO, North America, at Dr. Reddy’s Laboratories, goes inside the company’s new growth initiatives—and stretching the boundaries in healthcare exploration.

Introducing a new series highlighting ways pharma companies can up their game in winning earned media—and ultimately deliver greater impact and value from their messaging.

CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to recapture the heights of old.

The biosimilars market in the US is on the rise, but barriers to greater adoption remain.

Jan van de Winkel, PhD, president and CEO of Genmab, the longtime innovation engine in antibody drug development, discusses its vision for adding a new business identity: commercial driver.

Ken Keller, CEO of Daiichi Sankyo’s US business, reflects on the trials, triumphs, and lessons learned in steering the transformation of a legacy cardiovascular company into a global leader in oncology—advancing a vision for a reimagined future in cancer treatment.

Q&A with Evaluate’s Paul Verdin digs deeper into the data-backed drivers likely to sway the future growth and jockeying of biopharma’s top players.

Highlighted by notable company and product maneuvering at the top and the continued dramatic growth of therapeutic settings such as GLP-1s, Pharm Exec’s latest listing of the top global biopharma sales producers is proof-positive of an industry in transition.

How pharma and biotech leaders can navigate today’s challenging landscape—focusing on revamped approaches in business operations, talent strategy and development, and more to meet the evolving demands.

In this Pharmaceutical Executive video interview, Jesse Mendelsohn, senior vice president at Model N, discusses how more granular insights into channel, tracing, and chargeback data can help drugmakers make smarter provider and payer contracting decisions.